{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:01:13Z","timestamp":1787932873431,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Teaching Assistant and Research Assistant (TA\/RA) Scholarships from Chiang Mai University"},{"name":"the Distinguished Research Professor Grant of the National Research Council of Thailand","award":["NRCT808\/2563"],"award-info":[{"award-number":["NRCT808\/2563"]}]},{"name":"the Office of the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation (OPS MHESI), Thailand Science Research and Innovation (TSRI) and Chiang Mai University","award":["RGNS 64\u2014068"],"award-info":[{"award-number":["RGNS 64\u2014068"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02281-0","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:51:22Z","timestamp":1744343482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the immune effector functions induced by humanized anti-CD99 antibody in eliminating T lymphoblastic leukemia\/lymphoma cells"],"prefix":"10.1007","volume":"16","author":[{"given":"Kamonporn","family":"Kotemul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratthakorn","family":"Chaiwut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochetdhapada","family":"Putpim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supansa","family":"Pata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witida","family":"Laopajon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatchai","family":"Tayapiwatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watchara","family":"Kasinrerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuchjira","family":"Takheaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2281_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020;9:34.","journal-title":"Antibodies (Basel)"},{"key":"2281_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","volume":"80","author":"ML Grossbard","year":"1992","unstructured":"Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood. 1992;80:863\u201378.","journal-title":"Blood"},{"key":"2281_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.drudis.2012.04.006","volume":"17","author":"JM Reichert","year":"2012","unstructured":"Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today. 2012;17:954\u201363.","journal-title":"Drug Discov Today"},{"key":"2281_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/life12010048","author":"D Basak","year":"2021","unstructured":"Basak D, Arrighi S, Darwiche Y, Deb S. Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life. 2021. https:\/\/doi.org\/10.3390\/life12010048.","journal-title":"Life"},{"key":"2281_CR5","first-page":"233","volume":"5","author":"X Lyu","year":"2022","unstructured":"Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K, et al. The global landscape of approved antibody therapies. Antib Ther. 2022;5:233\u201357.","journal-title":"Antib Ther"},{"key":"2281_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43556-022-00100-4","volume":"3","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wang G, Lu H, Li H, Tang M, Tong A. Development of therapeutic antibodies for the treatment of diseases. Mol Biomed. 2022;3:35.","journal-title":"Mol Biomed"},{"key":"2281_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40164-022-00368-w","volume":"12","author":"D Caracciolo","year":"2023","unstructured":"Caracciolo D, Mancuso A, Poler\u00e0 N, Froio C, D\u2019Aquino G, Riillo C, et al. The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Exp Hematol Oncol. 2023;12:5.","journal-title":"Exp Hematol Oncol"},{"key":"2281_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.37349\/etat.2024.00207","volume":"5","author":"K Kotemul","year":"2024","unstructured":"Kotemul K, Kasinrerk W, Takheaw N. CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia. Explor Target Anti-tumor Ther. 2024;5:96\u2013107.","journal-title":"Explor Target Anti-tumor Ther"},{"key":"2281_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/jcp.2007.051144","volume":"61","author":"JD Edgar","year":"2008","unstructured":"Edgar JD. T cell immunodeficiency. J Clin Pathol. 2008;61:988\u201393.","journal-title":"J Clin Pathol"},{"key":"2281_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/sj.leu.2403303","volume":"18","author":"MN Dworzak","year":"2004","unstructured":"Dworzak MN, Fr\u00f6schl G, Printz D, Zen LD, Gaipa G, Ratei R, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18:703\u20138.","journal-title":"Leukemia"},{"key":"2281_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/antib13020042","volume":"13","author":"N Takheaw","year":"2024","unstructured":"Takheaw N, Kotemul K, Chaiwut R, Pata S, Laopajon W, Rangnoi K, et al. Transcriptome analysis reveals the induction of apoptosis-related genes by a monoclonal antibody against a new epitope of CD99 on T-acute lymphoblastic leukemia. Antibodies. 2024;13:42.","journal-title":"Antibodies"},{"key":"2281_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biom14111422","author":"N Takheaw","year":"2024","unstructured":"Takheaw N, Pamonsupornwichit T, Chaiwut R, Kotemul K, Sornsuwan K, Juntit OA, et al. Exploring the biological activity of a humanized anti-CD99 ScFv and antibody for targeting T cell malignancies. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14111422.","journal-title":"Biomolecules"},{"key":"2281_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0165-2478(99)00165-0","volume":"71","author":"W Kasinrerk","year":"2000","unstructured":"Kasinrerk W, Tokrasinwit N, Moonsom S, Stockinger H. CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway. Immunol Lett. 2000;71:33\u201341.","journal-title":"Immunol Lett"},{"key":"2281_CR14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00262-020-02789-0","volume":"70","author":"N Takheaw","year":"2021","unstructured":"Takheaw N, Sittithumcharee G, Kariya R, Kasinrerk W, Okada S. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma. Cancer Immunol Immunother. 2021;70:1557\u201367.","journal-title":"Cancer Immunol Immunother"},{"key":"2281_CR15","first-page":"7","volume":"3","author":"A Natsume","year":"2009","unstructured":"Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des Devel Ther. 2009;3:7\u201316.","journal-title":"Drug Des Devel Ther"},{"key":"2281_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2012.02.034","volume":"148","author":"M Weiner Louis","year":"2012","unstructured":"Weiner Louis M, Murray Joseph C, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148:1081\u20134.","journal-title":"Cell"},{"key":"2281_CR17","doi-asserted-by":"publisher","first-page":"eabl9171","DOI":"10.1126\/sciadv.abl9171","volume":"8","author":"X Cao","year":"2022","unstructured":"Cao X, Chen J, Li B, Dang J, Zhang W, Zhong X, et al. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Sci Adv. 2022;8:eabl9171.","journal-title":"Sci Adv"},{"key":"2281_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bmb\/lds032","volume":"104","author":"H Modjtahedi","year":"2012","unstructured":"Modjtahedi H, Ali S, Essapen S. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull. 2012;104:41\u201359.","journal-title":"Br Med Bull"},{"key":"2281_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri2744","volume":"10","author":"LM Weiner","year":"2010","unstructured":"Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317\u201327.","journal-title":"Nat Rev Immunol"},{"key":"2281_CR20","volume":"1","author":"P Kozani","year":"2021","unstructured":"Kozani P, Naseri A, Kozani P, Khatami S, Sheikhi A. Monoclonal antibodies (mAbs) approved for cancer treatment in the 2020s. Trends Med Sci. 2021;1: 116686.","journal-title":"Trends Med Sci"},{"key":"2281_CR21","first-page":"14","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.","journal-title":"Cancer Immun"},{"key":"2281_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-023-00384-4","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Zhu HH. Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12:30.","journal-title":"Exp Hematol Oncol"},{"key":"2281_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1309\/AJCPMF03LVSBLHPJ","volume":"144","author":"MJ You","year":"2015","unstructured":"You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia\/lymphoma. Am J Clin Pathol. 2015;144:411\u201322.","journal-title":"Am J Clin Pathol"},{"key":"2281_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","volume":"8","author":"S Shimony","year":"2024","unstructured":"Shimony S, DeAngelo DJ, Luskin MR. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2024;8:23\u201336.","journal-title":"Blood Adv"},{"key":"2281_CR25","first-page":"458","volume":"10","author":"UM Yildirim","year":"2023","unstructured":"Yildirim UM, Tekkesin F, Koc BS, Aydogdu S, Asarcikli F, Kilic SC. Acute complications observed during intensive chemotherapy in pediatric patients with acute lymphoblastic leukemia: Single-center experience. North Clin Istanb. 2023;10:458\u201369.","journal-title":"North Clin Istanb"},{"key":"2281_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081873","author":"E Genesc\u00e0","year":"2022","unstructured":"Genesc\u00e0 E, la Starza R. Early T-cell precursor all and beyond: immature and ambiguous lineage T-ALL subsets. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14081873.","journal-title":"Cancers"},{"key":"2281_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011374","volume":"97","author":"M Hu","year":"2018","unstructured":"Hu M, Wang H, Wang L, Yang M, Lou Y, Jin J. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation. Medicine. 2018;97: e11374.","journal-title":"Medicine"},{"key":"2281_CR28","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/eji.1830190813","volume":"19","author":"F Aubrit","year":"1989","unstructured":"Aubrit F, Gelin C, Pham D, Raynal B, Bernard A. The biochemical characterization of E2, a T cell surface molecule involved in rosettes. Eur J Immunol. 1989;19:1431\u20136.","journal-title":"Eur J Immunol"},{"key":"2281_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12079-017-0445-z","volume":"12","author":"M Pasello","year":"2018","unstructured":"Pasello M, Manara MC, Scotlandi K. CD99 at the crossroads of physiology and pathology. J Cell Commun Signal. 2018;12:55\u201368.","journal-title":"J Cell Commun Signal"},{"key":"2281_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5858\/2006-130-153-IOMCAT","volume":"130","author":"LC Kang","year":"2006","unstructured":"Kang LC, Dunphy CH. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Arch Pathol Lab Med. 2006;130:153\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"2281_CR31","doi-asserted-by":"publisher","first-page":"24374","DOI":"10.1038\/s41598-021-03929-x","volume":"11","author":"M Ebadi","year":"2021","unstructured":"Ebadi M, Jonart LM, Ostergaard J, Gordon PM. CD99 antibody disrupts T-cell acute lymphoblastic leukemia adhesion to meningeal cells and attenuates chemoresistance. Sci Rep. 2021;11:24374.","journal-title":"Sci Rep"},{"key":"2281_CR32","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.4049\/jimmunol.166.8.4931","volume":"166","author":"RD Pettersen","year":"2001","unstructured":"Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO. CD99 signals caspase-independent T cell death. J Immunol. 2001;166:4931\u201342.","journal-title":"J Immunol"},{"key":"2281_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167402","volume":"434","author":"LA Romero","year":"2022","unstructured":"Romero LA, Hattori T, Ali MAE, Ketavarapu G, Koide A, Park CY, et al. High-valency anti-CD99 antibodies toward the treatment of T cell acute lymphoblastic leukemia. J Mol Biol. 2022;434: 167402.","journal-title":"J Mol Biol"},{"key":"2281_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","volume":"6","author":"W Wang","year":"2015","unstructured":"Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.","journal-title":"Front Immunol"},{"key":"2281_CR35","doi-asserted-by":"publisher","first-page":"2191302","DOI":"10.1080\/19420862.2023.2191302","volume":"15","author":"P Cain","year":"2023","unstructured":"Cain P, Huang L, Tang Y, Anguiano V, Feng Y. Impact of IgG subclass on monoclonal antibody developability. mAbs. 2023;15:2191302.","journal-title":"mAbs"},{"key":"2281_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/mab.2016.0045","volume":"36","author":"Y Kato","year":"2017","unstructured":"Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, et al. antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Monoclon Antib Immunodiagn Immunother. 2017;36:20\u20134.","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"2281_CR37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/eji.202149766","volume":"52","author":"Y Wang","year":"2022","unstructured":"Wang Y, Kr\u00e9mer V, Iannascoli B, Goff OR-L, Mancardi DA, Ramke L, et al. Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species. Eur J Immunol. 2022;52:753\u20139.","journal-title":"Eur J Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02281-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T16:02:07Z","timestamp":1744387327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02281-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02281-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human study protocol mentioned in the statement received approval from the Ethics Committee of the Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand (AMSEC-64EX-016 and AMSEC-66EX-014). The study was performed following the Declaration of Helsinki.The animal use protocol was under the approval of the Chiang Mai University Animal Care and Use Committee (CMU ACUC; AUP Code 2565\/MC-0001, 2565\/MC-0005 and 2566\/MC-0006), Chiang Mai University, Chiang Mai, Thailand. All methods were carried out following relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"514"}}